title: RNAi-combined nano-chemotherapeutics to tackle resistant tumors.
abstract: The merger of nanotechnology and combination chemotherapy has shown notable promise in the therapy of resistant tumors. The latest scientific attention encompasses the engagement of anticancer drugs in combination with small interfering (si)RNAs, such as VEGF, XLAP, PGP, MRP-1, BCL-2 and cMyc, to name but a few. siRNAs have shown immense promise to knockout drug resistance genes as well as to recover the sensitivity of resistant tumors to anticancer therapy. The nanotechnology approach could also protect siRNA against RNAse degradation as well as prevent off-target effects. In this article, we discuss the approaches that have been used to deliver of siRNA in combination with chemotherapeutic drugs to treat resistant tumors. We also discuss the stipulations that must be considered in formulating a nanotechnology-assisted siRNA-drug cancer therapy.
authors.affiliation: National Institute of Pharmaceutical Education and Research (NIPER), Sarkhej - Gandhinagar Highway, Thaltej, Ahmedabad-380054, Gujarat, India. Electronic address: rakeshtekade@gmail.com.
authors.forename: Rakesh Kumar
authors.initials: RK
authors.lastname: Tekade
authors.affiliation: TIT College of Pharmacy, Technocrats Institute of Technology Campus, Anand Nagar, Raisen Road, Bhopal MP 462021, India.
authors.forename: Muktika
authors.initials: M
authors.lastname: Tekade
authors.affiliation: Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA.
authors.forename: Prashant
authors.initials: P
authors.lastname: Kesharwani
authors.affiliation: Leicester School of Pharmacy, De Montfort University, The Gateway, Leicester LE1 9BH, United Kingdom.
authors.forename: Antony
authors.initials: A
authors.lastname: D'Emanuele
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm; D006801:Humans; D036103:Nanotechnology; D009369:Neoplasms / Q000628:therapy*; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D034741:RNA, Small Interfering